Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M with Nivolumab and Cabiralizumab in Advanced Solid Tumors
NCT03502330Phase 1Completed
- Sponsor
- Yale University
- Start
- Jun 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotigalimab in melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), sponsored by Yale University. Started Jun 2018; status: completed.
02
Drugs
sotigalimab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03502330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502330.